Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F24%3A00013645" target="_blank" >RIV/00023736:_____/24:00013645 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00843989:_____/24:E0110993 RIV/00216224:14110/24:00135728 RIV/00216208:11140/24:10478853 RIV/00216208:11150/24:10478853 a 7 dalších

Výsledek na webu

<a href="https://doi.org/10.1038/s41375-024-02215-9" target="_blank" >https://doi.org/10.1038/s41375-024-02215-9</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/s41375-024-02215-9" target="_blank" >10.1038/s41375-024-02215-9</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF

Popis výsledku v původním jazyce

Tyrosine kinase inhibitor (TKI) therapy discontinuation with the aim of achieving treatment-free remission (TFR) is becoming more frequent, as an increasing number of chronic myeloid leukemia (CML) patients are achieving stable deep molecular response (DMR, i.e. BCR::ABL1 transcript level ≤0.01% on the International Scale), however, many challenges remain unresolved. Among others, a nonnegligible proportion of patients reported fear, anxiety, or depression both during TFR and when they had to reinitiate TKI therapy [2]. Similar negative feelings are frequently mentioned in the context of the decision to not stop TKI treatment, furthermore, a considerable proportion of patients (17–50%) have been reported to be unwilling to attempt TFR. However, little is known about how many truly eligible patients are unwilling to attempt TFR, the reasons for their decision and what factors are associated with their unwillingness to discontinue long-term therapy since the reports mentioned above have substantial limitations. The surveys were often conducted in a limited number of centres, focused on patients who are able to use internet tools, focused on more educated patients who are connected to patient supportive organisations, and usually not specifically focused on patients who fulfilled the criteria for TKI discontinuation.

Název v anglickém jazyce

Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF

Popis výsledku anglicky

Tyrosine kinase inhibitor (TKI) therapy discontinuation with the aim of achieving treatment-free remission (TFR) is becoming more frequent, as an increasing number of chronic myeloid leukemia (CML) patients are achieving stable deep molecular response (DMR, i.e. BCR::ABL1 transcript level ≤0.01% on the International Scale), however, many challenges remain unresolved. Among others, a nonnegligible proportion of patients reported fear, anxiety, or depression both during TFR and when they had to reinitiate TKI therapy [2]. Similar negative feelings are frequently mentioned in the context of the decision to not stop TKI treatment, furthermore, a considerable proportion of patients (17–50%) have been reported to be unwilling to attempt TFR. However, little is known about how many truly eligible patients are unwilling to attempt TFR, the reasons for their decision and what factors are associated with their unwillingness to discontinue long-term therapy since the reports mentioned above have substantial limitations. The surveys were often conducted in a limited number of centres, focused on patients who are able to use internet tools, focused on more educated patients who are connected to patient supportive organisations, and usually not specifically focused on patients who fulfilled the criteria for TKI discontinuation.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Leukemia

ISSN

0887-6924

e-ISSN

—

Svazek periodika

38

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

5

Strana od-do

893-897

Kód UT WoS článku

001183688000001

EID výsledku v databázi Scopus

2-s2.0-85187412156